https://wikem.org/w/index.php?action=history&feed=atom&title=Aminocaproic_acid 2026-04-19T22:03:24Z Revision history for this page on the wiki MediaWiki 1.38.2 https://wikem.org/w/index.php?title=Aminocaproic_acid&diff=389790&oldid=prev 2026-03-25T02:54:44Z

<p>Created Aminocaproic acid (Amicar) medication page with standard template</p> <p><b>New page</b></p><div>==Administration==<br /> *Type: [[Antifibrinolytic]]<br /> *Dosage Forms: tablet (500 mg, 1000 mg), oral solution (250 mg/mL), injection (250 mg/mL)<br /> *Routes of Administration: Oral, IV<br /> *Common Trade Names: Amicar<br /> <br /> ==Adult Dosing==<br /> ===Acute bleeding (general)===<br /> *Loading: 4-5 g IV or PO over first hour<br /> *Maintenance: 1-1.25 g/hr IV infusion OR 1-1.25 g PO q1h<br /> *Maximum: 30 g/day<br /> *Continue until bleeding controlled (typically 8-72 hours)<br /> <br /> ===Traumatic hyphema===<br /> *50 mg/kg PO q4h (max 30 g/day) for 5 days<br /> <br /> ===Oral bleeding (post-dental extraction in coagulopathic patients)===<br /> *Topical: swish and spit with oral solution<br /> *Systemic: 4-5 g PO loading, then 1 g q4-6h<br /> <br /> ==Pediatric Dosing==<br /> *Loading: 100-200 mg/kg IV or PO (max 5 g)<br /> *Maintenance: 100 mg/kg/dose q6h (max 30 g/day)<br /> <br /> ==Special Populations==<br /> ===[[Drug pregnancy categories|Pregnancy Rating]]===<br /> *C<br /> <br /> ===Lactation risk===<br /> *Unknown; use caution<br /> <br /> ===Renal Dosing===<br /> *Adult: Reduce dose in renal impairment (drug is renally excreted); contraindicated in upper urinary tract bleeding<br /> *Pediatric: Reduce dose proportionally<br /> <br /> ===Hepatic Dosing===<br /> *Adult: No specific adjustment; use with caution<br /> *Pediatric: No specific adjustment<br /> <br /> ==Contraindications==<br /> *Allergy to class/drug<br /> *Active intravascular clotting (DIC) — unless concurrent heparin is used<br /> *Upper urinary tract bleeding (risk of ureteral obstruction from clot)<br /> *History of thromboembolism without concurrent anticoagulation<br /> <br /> ==Adverse Reactions==<br /> ===Serious===<br /> *Thrombosis (DVT, PE, arterial thrombosis)<br /> *Rhabdomyolysis (with prolonged use)<br /> *Hyperkalemia<br /> *Seizures (with rapid IV infusion)<br /> <br /> ===Common===<br /> *Nausea, vomiting, diarrhea<br /> *Dizziness<br /> *Hypotension (with rapid IV administration)<br /> *Nasal congestion<br /> *Myalgia<br /> <br /> ==Pharmacology==<br /> *Half-life: 2 hours<br /> *Metabolism: Minimal hepatic metabolism<br /> *Excretion: Renal (65% excreted unchanged)<br /> <br /> ==Mechanism of Action==<br /> *Synthetic lysine analog that competitively inhibits plasminogen activation, thereby inhibiting fibrinolysis and stabilizing clot formation<br /> <br /> ==Comments==<br /> *Less commonly used than [[tranexamic acid]] (TXA) in the ED setting<br /> *TXA is generally preferred due to better evidence base and more favorable dosing<br /> *Unlike TXA, available as an oral solution (useful for swish-and-spit for oral bleeding)<br /> *Must infuse IV slowly (max 250 mL/h) to avoid hypotension and arrhythmias<br /> *Contraindicated in upper GU tract bleeding — clots can obstruct ureters<br /> *Monitor for signs of thrombosis, especially in patients with underlying hypercoagulability<br /> <br /> ==Indications by Condition==<br /> ''The following table is automatically generated from disease/condition pages across WikEM.''<br /> {{#ask:[[Has DrugName::Aminocaproic acid]]<br /> |?Has Indication=Indication<br /> |?Has Dose=Dose<br /> |?Has Context=Context<br /> |?Has Route=Route<br /> |?Has Population=Population<br /> |format=table<br /> |headers=plain<br /> |mainlabel=-<br /> |sort=Has Indication<br /> |limit=50<br /> }}<br /> <br /> ==See Also==<br /> *[[Tranexamic acid]]<br /> *[[Anticoagulant reversal for life-threatening bleeds]]<br /> *[[Coagulopathy (Main)]]<br /> <br /> ==References==<br /> &lt;references/&gt;<br /> <br /> [[Category:Pharmacology]]</div>

Danbot